INTRODUCTION
Lung cancer is the leading cause of cancer death in the United States and worldwide (16) .
In most cases, the main cause of death from lung cancer relates to tissue invasion and metastasis by carcinoma cells (7) (8) . One of the first steps in tumor metastasis is the acquisition of cellular motility and invasiveness. During this process, tumor cells partially lose their epithelial markers and gain mesenchymal characteristics, a process termed epithelial mesenchymal transition (EMT). EMT has been recognized as a central feature of normal embryonic development, governing the formation of gastrula, neural crest and the heart, but recent studies have revealed that a similar transition occurs during the progression of tumors, and much evidence has accumulated in favor of a role for EMT in tumor metastasis (20, 49) . Thus, defining the factors that promote EMT in the setting of lung carcinoma is likely to lead to the identification of new targets for therapy.
Tumor cell-stroma interactions are becoming increasingly recognized as important determinants of tumor cell fate (6) (7) 50 ). Studies in human lung, breast, colon and prostate cancer showed that carcinoma cells are submerged in a microenviroment with fibroblasts and extracellular matrix (ECM) proteins such as fibronectin, collagens, tenascins, proteoglycans, glycosaminoglycans and laminin (6-7, 35, 50) . As the result of complex interactions between cells and their surrounding stroma, ECMs may affect tumor cell behavior including metastasis (28, 41) . Fibronectin is among the ECM proteins present in tumor tissue, and the fragmentation of pericellular fibronectin with the exposure of cryptic molecular binding sites is considered an early sign of malignancy (24) . Interestingly, the amount of fibronectin in stroma has been found to be 7-13 times higher in carcinoma as compared with normal tissue (32) . Furthermore, we and others have reported that fibronectin promotes cancer cell proliferation through effects on pro- (11, 13, 15) . These and other observations have prompted investigations into fibronectin as a potential target for tumor therapy (22) .
Fibronectin is a high-molecular-weight adhesive glycoprotein that exists in two main forms, as an insoluble glycoprotein dimer present within the ECM or as a soluble disulphidelinked dimer in plasma. Each dimer consists of two nearly identical polypeptide chains and three types of homologous repeating modules termed types I, II, and III (40). Cells may recognize fibronectin through one or more receptors of the integrin family. Eleven different integrin heterodimers have been found to bind to fibronectin, and four of them, α5β1, αvβ3, α4β1 and αIIbβ3, trigger fibronectin fibril formation in vitro (25) . The integrin α5β1 is the best studied fibronectin-binding integrin, it recognizes the minimal integrin recognition peptide sequence Arg-Gly-Asp (RGD) within the fibronectin monomer (34) .
Different isoforms of fibronectin are generated by alternative splicing of combinations of three exons: extra domain A (EDA/EIIIA), extra domain B (EDB/EIIIB), and connecting segment III (V). The so-called plasma fibronectin (pFN), produced by hepatocytes and abundant in plasma, lacks both the EDA and EDB domains (34, 40) , while cellular fibronectin (cFN), produced by fibroblasts, epithelial cells and other cell types, contains the EDA and/or EDB segments. Although the functions of EDA and EDB domains have not been fully elucidated, their ablation leads to embryonic lethality within EDA/EDB double-null animals (2).
Fibronectin containing EDA has been implicated in the regulation of wound healing (9) , and is more potent than fibronectin lacking EDA in promoting cell spreading and cell migration irrespective of the presence or absence of EDB (29) . The EDGIHEL sequence within the EDA variant facilitates binding to α4β1 and α9β1 integrins (26, 43).
In this report, we show that cFN-EDA prevents the clustering of lung adenocarcinoma cells resulting in cell scattering (a marker of EMT), promotes cell migration and invasion, and regulates the expression of EMT protein markers through PI3-K and Erk pathways. Furthermore, we show that the cFN-EDA exerts these effects through binding to α9 integrin receptors.
MATERIALS AND METHODS

Cell culture
The human NSCLC cell lines A549 and H1792 were obtained from the American Type Culture Collection and were maintained in DMEM or RPMI 1640 medium supplemented with 10% FBS (Hyclone, Logan, UT) and 50 IU/ml penicillin/streptomycin at 37 °C in 5% CO 2 , respectively.
Reagents and antibodies
The following reagents were used: human cFN (Sigma), Collagen type 1 (Boehringer mannheim), pFN (Sigma), TGF-β (BD Biosciences), α9 integrin subunit siRNA (Santa Cruz Biotechnology), α5 integrin subunit siRNA (Santa Cruz Biotechnology), and DAPI (Santa Cruz Biotechnology). cFn was dissolved in PBS and incubated directly with culture medium afterwards. Antibodies against the following proteins were used: anti-E-cadherin (BD Biosciences), anti-α-SMA (Santa Cruz Biotechnology), anti-p-Akt, anti-p-Erk, anti-total Akt and total Erk (Cell Signaling), anti-GAPDH (Sigma), goat anti-rabbit HRP secondary antibody (Sigma) and goat anti-mouse HRP secondary antibody (Santa Cruz Biotechnology). 
Invasion assay
The invasive ability of H1792 and A549 cells was assayed as follows. Inserts pre-coated with Matrigel (Costar) were pre-incubated with complete medium containing 1% FBS in 37°C for 1 h before the cells were plated. Then, the media was replaced with 5x10 
Immunofluorescence analysis
A549 and H1792 cells were plated onto 8-well glass chamber slides (3,000 cells per well) for immunostaining. Cells were treated with 20 μg/ml cFN for the indicated time points. They were fixed with 10% buffered-formalin and double immunofluorescence staining was performed following a previous published protocol (36). Primary antibodies used were mouse monoclonal IgGs against human E-cadherin (1:3000 dilution) and α-SMA (1:500 dilution). Secondary antibodies used included goat anti-mouse Alexa Fluor-488 (1:200 dilution). DAPI was used to stain the nuclei.
Western Blot analysis
The procedure was performed as previously described (12) . Briefly, cells were harvested, lysed, and analyzed, and protein concentrations were determined by the Bio-Rad protein assay.
Equal amounts of protein from whole-cell lysates were solubilized in 2Х SDS sample buffer and separated on SDS polyacrylamide gels. Blots were incubated with primary antibodies against Ecadherin (1:3,000, 30 min at room temperature), α-SMA (1:500), p-Erk (1:500), or p-Akt (1:500) overnight at 4°C. After washing, the blots were washed and incubated with a secondary antibody against rabbit (1:2,000) or mouse (1:5,000) IgG conjugated to horseradish peroxidase.
The blots were washed, transferred to freshly made chemiluminescence solution for 1 min, and
2 0 1 0 8 exposed to X-ray film. In controls, the primary antibodies were omitted or replaced with a control rabbit IgG.
Preparation of fibronectin-derived matrices with different amounts of EDA
Wild-type C57Bl/6 murine lung fibroblasts (with normal splicing of EDA), EDA-/-lung fibroblasts (lacking the EDA domain or EDA+/+ lung fibroblasts (incorporating EDA into all fibronectin molecules) were previously described (33) . Primary lung fibroblasts were generated as we have previously described (52). For generation of matrices, fibroblasts were cultured until 5 to 7 days post-confluence, changing media every other day. Subsequently, cells were washed with 1mM EDTA and incubated for 30 minutes in EDTA with protease inhibitors at 4 o C. These steps were repeated twice prior to washing in 1M NaCl with EDTA and protease inhibitors to lyse any remaining nuclei and remove cell debris. Matrices were then washed three times in cold HBSS followed by blocking in 10% BSA for 2 hours and extensive washing with PBS. Plates were stored at 4°C until use. Random plates were assayed for complete cell removal by immunofluorescence with DAPI (not shown).
Construction of plasmid EDA-FLAG and transient transfection
The following primers were designed to amplify the EDA exon regions of the human fibronectin gene: EDA forward primer, 5' CCCAAGCTTAACATTGATCGCCCTAAAGGA, and reverse primer, 5' CCCGGTACCTGTGGACTGGGTTCCAATCAGG, using RNA isolated from human lung fibroblasts (IMR90). The 290 base pair EDA PCR products were separated on a 1% agarose gel and the DNA was extracted and purified using Spin-X (Costar) and Centricep (Princeton Separations) columns. Afterwards, purified products were ligated into the p3xFlag- confluence. For cell scattering assays, the cells were transfected with α5 or α9 siRNA following the same procedure before and after cFN treatment for 24 h.
Statistical analysis
All experiments were repeated a minimum of at least three times. All data were expressed as means ± SD. The data presented in some figures are from a representative experiment which was qualitatively similar in the replicate experiments. Statistical significance was determined with Student's t-test (two-tailed) comparison between two groups of data sets.
RESULTS cFN induces lung adenocarcinoma cell scattering in vitro
To assess the effect of fibronectin on tumor cell organization in culture, A549 and H1792 lung adenocarcinoma cells were plated in 6-well plates and treated with cFN for 24-96 h.
Examination of their morphology showed that untreated cells grew in clusters or clumps. In contrast, when treated with cFN, cells remained scattered, and only few colonies were formed 72 h later (Fig. 1A, C) . cFN induced the elongation of cells, which took a fibroblast-like shape.
The same effects were found in an additional cell line, H1792 (Fig. 1B, C) . As TGF-β is a wellknown inducer of EMT in many carcinoma cells (53), it was used in this assay as a positive 
cFN promotes lung adenocarcinoma cell migration and invasion
To examine whether cFN promotes cell migration, A549 cells were grown to 90% confluence and submitted to an in vitro "wound healing assay". After 24 h of exposure to cFN, significant migration was noted with almost complete (75%) obliteration of the wounded area, but no obvious effects were observed for type 1 collagen and pFN ( Therefore, we tested the effect of cFN on E-cadherin expression. In A549 cells, E-cadherin staining (red) was decreased after 72 h of cFN treatment (Fig. 3A) . In contrast, staining for the classic mesenchymal marker, α-smooth muscle actin (SMA), was increased (green) (Fig. 3B) .
These results were also confirmed by Western blot as shown in Fig. 3C and 3D in a time-and dose-dependent manner with cFN treatment. Note that untreated control cells showed no changes in the expression of E-cadherin for the same period of time, and that pFN had no effect on E-cadherin (supplementary Fig. 1-2) . Similar results were also observed in H1792 (not shown).
PI3-K/Akt and Erk are involved in cFN-induced EMT
We previously demonstrated that fibronectin promotes cell proliferation through increased phosphorylation of the PI3-K down stream signal Akt and of Erk in NSCLC cells (13) (14) . Thus, we examined whether these pathways mediated the effect of cFN. We found that the PI3-K inhibitor, wortmannin, and the Erk inhibitor, PD98059, blocked the effect of cFN on E-cadherin and α-SMA expression, while the inhibitor of PKA H-89 had no effect (Fig 4A) . Moreover, the first two inhibitors also significantly diminished cFN-induced A549 cell scattering, although the effect was not dramatic, suggesting the involvement of the pathways in cFn-induced EMT (Fig.   4B ).
To further test the effect of cFN on these kinases, we evaluated if cFN induces the phosphorylation of Akt and Erk starting at 15 min (Fig. 4C) ; it did. The inhibitor of Akt had no effect on cFN-induced Erk activation (Fig. 4D) . Similarly, the inhibitor of Erk had no effect on (Fig. 4D) . Therefore, these kinases appear to influence EMT via distinct pathways.
The EDA domain in cFN is responsible for cFN-induced EMT
To test the role of the EDA domain in cFN-induced EMT, the cells were cultured in plates pre-coated with three types of matrices: 1) matrices derived from fibroblasts expressing wild type fibronectin EDA, 2) matrices derived from fibroblasts expressing fibronectin deficient in EDA (EDA-/-ECM), and 3) matrices derived from fibroblasts constitutively expressing the fibronectin EDA splicing variant (EDA+/+ ECM). Few loose and small colonies companied by surrounding scattered cells were found with EDA+/+ ECM, while an increased number of compact colonies was observed in EDA-/-ECM (Fig. 5A ). Of note, changes noted in cells cultured on EDA+/+ ECM were associated with increased phosphorylation of Akt and Erk (Fig.   5D ).
We then tested the effect of EDA overexpression on cFN-induced EMT using cells transfected with a plasmid containing EDA-Flag. The strategy for the generation of cells expressing the EDA vector is shown in Figure 5B . The effectiveness of transfection of increasing concentration of the EDA-vector into NSCLC cells was examined by determining EDA-Flag protein expression (Fig. 5C) . Note that the non-vector and control vector had no EDA-Flag protein (Fig. 5C ). Consistent with a role for EDA in EMT, we showed that exogenous expression of EDA decreased E-cadherin, but it increased α-SMA expression in A549 cells (Fig. 5C ). These effects were associated with phosphorylation of Erk and Akt as determined by Western blot analysis (Fig. 5D ). Similar observations were found in H1792 (not shown). Having established that the EDA domain of cFN stimulates EMT through the phosphorylation of Akt and Erk, we set out to investigate the receptor mediating these effects.
Integrin receptors are required for fibronectin to bind to cells and stimulate signal transduction.
Besides the classic fibronectin receptor α5β1, many integrins are able to bind fibronectin. To assess which integrin mediates cFN-induced EMT, we examined the effects of silencing of the α5, α9 and α4 integrin subunits on A549 cells. We found that silencing of α9, but not α5 integrin subunit, significantly diminished cFN-induced cell scattering, allowing for the formation of more colonies (Fig. 6A ). In addition, silencing of α9 also largely decreased cFN-induced cell migration (Fig. 6B), invasion (Fig. 6C, upper panel) and blocked cFN-induced α-SMA and the expected decrease in E-cadherin protein expression (Fig. 6C, lower panel) . Furthermore, silencing of α9 abrogated cFN-induced phosphorylation of Akt and Erk (Fig. 6D) . Note that silencing of α4 integrin subunit had no effect (not shown). Similar observations were also found in H1792 (not shown). These data suggest that the integrin α9 subunit mediates cFN-induced EMT. Another factor capable of promoting EMT is the stroma. The proliferation of fibroblasts, accompanied by an accumulation of connective tissue, is a typical feature in many solid tumors (3, 24, 50) . Also, factors associated with increased incidence of lung cancer (e.g. nicotine and alcohol exposure) promote the deposition of ECM in lung (4, 38) . Hypoxia, considered a promoter of tumor progression, also stimulates matrix deposition (18) . Thus, there appears to be an association between carcinoma development and tissue fibrosis. One ECM component found to be increased in the setting of lung cancer is fibronectin (24) . In this work, we demonstrate that fibronectin not only stimulates lung cancer cell growth as we previously reported, but it also promotes EMT through the repression of epithelial cell markers and the induction of a mesenchymal phenotype. This leads to enhanced cell migration and invasion in NSCLC cells.
DISCUSSION
Note that fibronectin is secreted by cells in a soluble fashion and then incorporated into an insoluble matrix in the presence of cells. This process is considered to be dependent on cell surface integrin receptors (27, 42). We have found that monocytic cells, fibroblasts, and carcinoma cells respond to fibronectin in a similar fashion independent of its presentation (i.e., insoluble versus soluble). However, we try to engage primarily in experiments that use soluble fibronectin in order to avoid the confounding effects related to cytoskeletal organization and cell shape changes seen when cells are cultured on insoluble substrates. These, in the end, are difficult to avoid, but using soluble fibronectin diminishes this concern. In exploring the signaling pathways involved in EMT, it was reported that inhibition of Akt activity leads to mesenchymal-epithelial transition (MET) with restoration of E-cadherin expression in oral squamous cell carcinoma cells (19) . Previously, we showed that fibronectin stimulates lung cancer cell proliferation through the phosphorylation of molecules involved in the PI3-K/Akt and Erk pathways (11, 13) . The work presented here suggests that Akt and Erk are also involved in cFN-induced EMT. Of note, no cross talk between Akt and Erk was detected suggesting that cFN induces EMT through Akt and Erk pathways that appear to be independent from each other. We realize the chemical inhibitors are not specific. Because of the limitation of this approach, more specific approaches such as siRNA knockdown of Erk and Akt will be used in the future. Also, those signaling pathway might be important. (23) . Similarly, we found that blockade of TGF-β1 signaling by inhibition of the TGF-β1 receptor abrogated the effect of cFN-induced EMT (supplementary Fig. 3 ). This suggests that TGF-β1 signaling might also contribute to involves in cFN-induced EMT. Further studies will explore the role of Smad signaling in this process.
Finally, we examined the identity of the integrin receptors mediating cFN-induced EMT.
Integrins are heterodimeric transmembrane proteins composed of α and β subunits that mediate cell-cell and cell-matrix interactions (21) . Once activated, integrins transmit signals that connect cell surface stimulation to the cytoskeleton and the transcription machinery. Importantly, integrins play different roles in cellular processes related to growth, survival, apoptosis, and differentiation. The α5β1 integrin is considered the major receptor for fibronectin, and it recognizes the RGD motif in its ligand (48). Our previous studies showed that α5β1 integrin contributes to lung cancer cell proliferation through the activation of multiple oncogenic pathways (37). More recently, we reported that silencing of α5β1 via shRNA prevents tumor progression in an animal model (39). Here, we show that the integrin α9β1 might also mediate recognition of fibronectin. α9β1 is also a receptor for VCAM1, is expressed in many mammalian tissues, and can mediate accelerated cell migration (10, 45). The integrin α9β1 has been found to be upregulated in small cell lung cancers (17) . Others have shown that the EDA portion of cFN binds α9β1 (44). EDA-α9β1 interactions were reported to be crucial for efficient and proper re-epithelialization during cutaneous wound healing (45-46). Considering the above, we tested the roles of both the α5β1 and α9β1 in cFN-induced EMT. We showed that knockdown of α9, but not α5 integrin, reduced the response of cells to cFN, suggesting that α9 integrin mediates cFN-induced EMT, at least in part, through interactions with EDA. However, 
